[1] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[2] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[3] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|
[4] |
ZOU Dongmei, FANG Fang, GUO Yixian, NI Jing, ZHAO Hong, HU Ronghua, SUN Wanling.
Analysis of the association of adverse reactions with relative dose of melphalan and body weight in POEMS syndrome patients undergoing melphalan-based ASCT
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 911-914.
|
[5] |
LIANG Shibing, YU Zeyu, KONG Lingyao, YAN Lijiao, HAN Mei, WU Jiarui, LIU Zhaolan, LIU Jianping.
Applicability of bibliometric methods pharmacovigilance of traditioual Chinese medicine
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 591-594.
|
[6] |
JIAO Fuzhi, CHEN Yarui, JI Wei, HAO Jianpeng, GUAN Quanlin.
Short-term efficacy and safety evaluation of PD-1 inhibitor combined with chemotherapy as a first-line neoadjuvant therapy for locally advanced gastric adenocarcinoma
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 301-305.
|
[7] |
JIANG Jiandong.
Development and clinical safety of paediatric medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 1-6.
|
[8] |
LIU Zhike, ZHAN Siyan.
Progress in applications of self-controlled designs in association study of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 74-78.
|
[9] |
WANG Juli, ZHANG Xiaomeng, ZHANG Bing, LYU Jintao.
Safety of medications for cardiovascular diseases in community clinics
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 744-748.
|
[10] |
CUI Can, WEI Hongtao, CHENG Sheng, SHEN Su.
Adverse reactions induced by teriparatide
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 333-335.
|
[11] |
LIU Min, PEI Xiaojing, WANG Haixue.
Problems with and suggestions about expedited reporting of suspected unexpected serious adverse reactions during clinical trials of drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 176-179.
|
[12] |
HUANG Liting, TANG Zaixiang, BAI Lu, SHI Guanhong, JIANG Yiguo.
Adverse reactions of benzodiazepines based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1223-1227.
|
[13] |
WU Chen, LIU Cuili, WANG Tao.
Cardiovascular safety of haloperidol preparations
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1100-1102.
|
[14] |
WU Yingqi, ZHU Ting, TONG Tong, LI Min, SHEN Aizong.
Factors related to ADR/ADE of albumin bound paclitaxel
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1123-1127.
|
[15] |
WANG Wen, LIU Mei, HE Qiao, TIAN Chunhua, SONG Haibo, WANG Tao, TAN Jing, REN Yan, GAO Pei, PENG Xiaoxia, WEN Zehuai, SHU Xiaochen, ZOU Kang, SHEN Chuanyong, SUN Xin.
Expert consensus on design and statistical analysis to evaluate drug safety using routinely collected health data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 7-12.
|